Clinical Trials Logo

Wernicke Encephalopathy clinical trials

View clinical trials related to Wernicke Encephalopathy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03466528 Completed - Alcohol Withdrawal Clinical Trials

Alcohol: Thiamine and or Magnesium 1

AToM1
Start date: December 16, 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Patients who suffer Alcohol Use Disorder (AUD) have a 30-80% incidence of thiamine deficiency causing Wernicke's Encephalopathy (WE). Intravenous (IV) thiamine replacement is standard practice in the treatment of alcoholic patients presenting to the Accident & Emergency (A&E) department, however routine co-supplementation with magnesium (administered IV as magnesium sulphate ), which is required as a co-factor for thiamine in some metabolic processes, e. g. on the activity of the enzyme transketolase in red blood cells, is not routine practice in the treatment of these patients. Without correction of concomitant magnesium deficiency there may be impaired utilisation of thiamine resulting in a failure to treat WE. This study is designed to determine if administration of magnesium to AUD patients affects red cell transketolasae and serum lactate concentrations by itself, or only acts to increase the effect of thiamine on the activity of this enzyme.

NCT ID: NCT02788552 Completed - Clinical trials for Wernicke-Korsakoff Syndrome

Optimum Thiamine Intervention (OpTIn) Trial

OpTIn
Start date: September 2014
Phase: Phase 4
Study type: Interventional

Wernicke-Korsakoff syndrome (WKS), once thought to be a rare condition, is now known to be common in people with nutritional deficiencies or alcohol dependence. The primary cause of WKS is thiamine deficiency, and more than 90% of cases are reported in alcohol dependent patients because alcohol dependence predisposes to severe nutritional deficiency. WKS may lead to significant, long-term brain dysfunction with severe effects on work, personal and social function. Whilst effective treatment may greatly reduce severe disability and the human and social costs of this illness, almost no evidence exists on optimal dosing regimens. This project proposes to develop quality evidence for effective treatment of WKS in an Aboriginal setting.